Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Change in Receivables: 2015-2025

Historic Change in Receivables for CorMedix (CRMD) over the last 8 years, with Sep 2025 value amounting to $87.3 million.

  • CorMedix's Change in Receivables rose 407.94% to $87.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $112.9 million, marking a year-over-year increase of 557.31%. This contributed to the annual value of $51.8 million for FY2024, which is N/A change from last year.
  • Latest data reveals that CorMedix reported Change in Receivables of $87.3 million as of Q3 2025, which was up 845.48% from -$11.7 million recorded in Q2 2025.
  • Over the past 5 years, CorMedix's Change in Receivables peaked at $87.3 million during Q3 2025, and registered a low of -$11.7 million during Q2 2025.
  • In the last 2 years, CorMedix's Change in Receivables had a median value of $17.2 million in 2024 and averaged $26.0 million.
  • Data for CorMedix's Change in Receivables shows a peak YoY increase of 1,825.73% (in 2021) and a maximum YoY decrease of 1,290.70% (in 2021) over the last 5 years.
  • Over the past 4 years, CorMedix's Change in Receivables (Quarterly) stood at $47,354 in 2021, then plummeted by 99.07% to $440 in 2022, then reached $34.4 million in 2024, then skyrocketed by 407.94% to $87.3 million in 2025.
  • Its Change in Receivables was $87.3 million in Q3 2025, compared to -$11.7 million in Q2 2025 and $3.0 million in Q1 2025.